Crysvita® (burosumab-twza) – New indication
June 18, 2020 - The FDA announced the approval of Kyowa Kirin and Ultragenyx’s and Crysvita (burosumab-twza), for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
Top